Efficacy of chelation therapy in hyperuricemic patients unresponsive to oral uric acid lowering agent
10.32581/jkifm.2024.7.2.82
- Author:
Hyang-Rae LEE
1
;
Seok-Hoon LEE
;
Nam-Seok JOO
Author Information
1. Department of Family Practice and Community Health, Ajou University School of Medicine, Suwon, Korea
- Publication Type:Case Report
- From:
Journal of Korean Institute for Functional Medicine
2024;7(2):82-88
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hyperuricemia occurs due to purine metabolism disorders, with serum uric acid levels exceeding 7 mg/dL in men and 6 mg/dL in women. It increases the risk not only of gout but also of metabolic diseases such as hypertension, non-alcoholic fatty liver disease, chronic kidney disease, and cardiovascular diseases. Ethylenediaminetetraacetic acid chelation therapy, traditionally used for removing heavy metals, has also shown potential in preventing cardiovascular diseases. This case report aims to assess the effectiveness of chelation therapy in patients with hyperuricemia who do not respond to conventional oral uric acid-lowering drugs. This could expand the scope of functional medicine and provide an alternative treatment strategy for patients unresponsive to traditional medications.
